International Clinical Trial: A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07725796) titled 'A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC' on July 21.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.

Condition: Bladder (Urothelial, Transitional Cell) Cancer NMIBC Urothelial Carcinoma Bladder Urothelial Carcinoma in Situ Urothelial Carcinoma Recurrent Urothelial Carcinoma of the Urinary Bladder Non-Muscle Invasive Bladder Carcinoma Non-muscle Invasiv...